Amsoki-cel ORR was 67% at RP2D (n=10/15), including 2 CRs and 8 PRs; 5 responses remain ongoing, including both CRs and 2 PRs with 100% SOD reduction (one of which deepened since the abstract data
Obsidian Therapeutics, Inc. ("Obsidian") (NASDAQ:OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell
Following discussions with FDA, Company has decided to pursue a single-arm trial design intended to support future BLA submission
Initiation of registration-enabling cohort follows positive Phase 1/2 results
Obsidian Therapeutics to focus on the advancement of its pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors
Post-transaction cash and cash equivalents of approximately
